Did UnitedHealth Name The Fix Before Its Stock Ran?

UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.

What Did UnitedHealth Say It Would Give Up?

In July 2025 the company said its 2026 pricing was built around margin recovery, and it named the bill. It would exit plans serving over 600,000 members, mostly less managed products such as PPO offerings. It was narrowing its Medicare Advantage networks.

There was a lot to recover. As of fiscal Q4 2025, the last set of results filed before the run began, UnitedHealth’s trailing-twelve-month operating margin was 4.2%, against a three-year average of 7.8%. Revenue over the same twelve months still grew 11.8%, showing volume and demand remained intact. The problem was that medical costs severely outpaced premiums—pricing had failed to keep up with trend.

By October 2025 the company said the repricing at UnitedHealthcare was on track to lift that business’s 2026 operating earnings through margin improvement. In January 2026 it sized the retreat: Medicare Advantage membership would contract by 1.3 million to 1.4 million across 2026, an approach it said favored margin recovery. It was also targeting operating cost reductions of nearly $1 billion.

Has UnitedHealth Collected On That Trade?

It has. Adjusted earnings per share in fiscal Q2 2026 were $6.38, against $4.08 a year earlier. In July 2026, with the run already under way, it raised its full-year 2026 adjusted earnings outlook to a range of $19.50 to $20 a share. In January 2026 that outlook had been greater than $17.75. Revenue in fiscal Q2 2026 was largely consistent with the prior year, so the improvement did not come from selling more.

The payoff came largely from the levers the plan laid out, alongside operational adjustments like benefit design and care management, with the final figures landing better than anticipated. Medicare medical cost growth for 2026 is now expected to land below the initial estimate of around 10%. Management attributes that partly to its own benefit design, care management and network curation. The membership bill came in lighter too: Medicare Advantage enrollment is now expected to fall by about 1.1 million for 2026, against the 1.3 million to 1.4 million it had planned.

Did Anticipating The Turn Actually Pay Off?

Partly. The plan was legible and the timing was not. Implied volatility on UNH options climbed from the 37th percentile of its trailing one-year range in early February 2026 to the 91st by mid-March. That said a large move was coming in either direction, and nothing about which one.

The reward was not UnitedHealth’s alone either. Elevance Health (ELV) returned 40.3%, a shade ahead of UnitedHealth’s 40.0%, while CVS Health (CVS) returned 24.0% and Cigna (CI) 5.9% over the same window, so reading this plan early bought no more than owning the closest peer did. What the plan has still not fixed is the commercial book, where management now expects full margin recovery to run past 2027. That is what is left to watch, and our guidance momentum screen is where the next company to move its outlook will show up.

So Do You Own It After The Run?

Perhaps, but you would be paying for a repair that has already happened. The plan is no longer news and what is left is execution on the commercial book. Before you pay up for one company’s turn, see how the rest of the group screens on the same question. If you would rather not pick one name at a time, look at the Trefis High Quality Portfolio. That portfolio has a track record of outpacing its benchmark—a blend of the three major indices.